T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Growth and characterization of epithelial cells from normal human uterine ectocervix and endocervix.
TL;DR: HEnE and HEcE cells may be useful in developing in vitro models of cervical squamous metaplasia and for exploring the interactions between target cell differentiation, carcinogens, and papillomaviruses in the development of cervical neoplasia.
Journal ArticleDOI
Genomic approaches to the pathogenesis of hematologic malignancy.
TL;DR: An overview of the basic technologies underlying genome-wide molecular classification of human acute leukemias and lymphomas and of initial attempts to define oncogene-mediated transcriptional programs using DNA microarrays are provided.
Journal ArticleDOI
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.
Phillip G. Febbo,Aaron R. Thorner,Mark A. Rubin,Massimo Loda,Philip W. Kantoff,William Oh,Todd R. Golub,Daniel J. George +7 more
TL;DR: This study shows that high-quality microarray data can be generated using LCM and RNA amplification to discover potential mechanisms of targeted therapy in cancer, and suggests that imatinib mesylate therapy results in apoptosis of microvascular endothelial cells, an observation anecdotally supported by immunohistochemistry.
Journal ArticleDOI
Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors.
Elaine M. Oberlick,Elaine M. Oberlick,Matthew G. Rees,Brinton Seashore-Ludlow,Brinton Seashore-Ludlow,Francisca Vazquez,Geoffrey M. Nelson,Neekesh V. Dharia,Barbara A. Weir,Aviad Tsherniak,Mahmoud Ghandi,John M. Krill-Burger,Robin M. Meyers,Xiaofeng Wang,Phil Montgomery,David E. Root,Jake M. Bieber,Sandi Radko,Jaime H. Cheah,C. Suk-Yee Hon,Alykhan F. Shamji,Paul A. Clemons,Peter J. Park,Michael A. Dyer,Todd R. Golub,Todd R. Golub,Kimberly Stegmaier,Kimberly Stegmaier,Kimberly Stegmaier,William C. Hahn,William C. Hahn,William C. Hahn,Elizabeth Stewart,Stuart L. Schreiber,Stuart L. Schreiber,Charles W. M. Roberts +35 more
TL;DR: It is demonstrated that large-scale perturbational screening can uncover vulnerabilities in cancers with "quiet" genomes by revealing several receptor tyrosine kinases (RTK) as therapeutic targets.
Journal ArticleDOI
A Maltose-Binding Protein Fusion Construct Yields a Robust Crystallography Platform for MCL1.
Matthew C. Clifton,David M. Dranow,Alison Leed,Ben Fulroth,James W. Fairman,Jan Abendroth,Kateri Atkins,Ellen Wallace,Dazhong Fan,Guoping Xu,Z. J. Ni,Douglas S. Daniels,John Van Drie,Guo Wei,Alex B. Burgin,Todd R. Golub,Todd R. Golub,Brian K. Hubbard,Michael H Serrano-Wu +18 more
TL;DR: In the ligand-independent crystal form, this MBP-MCL1 construct dramatically improves the structural understanding of well-validated MCL1 ligands, and will likely catalyze the structure-based optimization of high affinity M CL1 inhibitors.